Schüpke S, Neumann FJ, Menichelli M, et al. - Through a multicenter, randomized, open-label trial of a total of 4,018 patients with acute coronary syndromes for whom the invasive assessment is planned, experts determined the relative benefits of ticagrelor in comparison with prasugrel. In 1.3% and 1.0% of patients assigned to ticagrelor and to prasugrel, definite or probable stent thrombosis occurred, and definite stent thrombosis occurred in 1.1% and 0.6%, respectively. The incidence of death, myocardial infarction, or stroke was significantly lower among those who received prasugrel vs ticagrelor, amongst patients who presented with acute coronary syndromes with or without ST-segment elevation, and the incidence of major bleeding was not significantly distinctive among the two groups.